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www.rsc.org/medchemcommSynthesis of a new HYNIC-DAPI derivative for
labelling with 99mTechnetium and its in vitro
evaluation in an FRTL5 cell line
Sandra Ferl,*a Gerd Wunderlich,a René Smits,b Alexander Hoepping,b
Anne Naumanna and Jörg Kotzerkea
4′,6-Diamidine-2-phenylindole (DAPI) is a common fluorochrome that is able to bind to deoxyribonucleic
acid (DNA) with distinct, sequence-dependent enhancement of fluorescence. This work presents the syn-
thesis of a new multifunctional compound that includes the fluorescent dye as a 99mTechnetium (99mTc)
carrier. A new technique for the bioconjugation of DAPI with 6-hydrazinonicotinic acid (HYNIC) through
an amide linkage was developed. The radiolabelling was performed with HYNIC as a chelator and
N-Ĳ2-hydroxy-1,1-bisĲhydroxymethyl)ethyl)glycine (tricine) as a coligand. Furthermore, experimental evi-
dence showed that 99mTc complexes with DAPI as DNA-binding moieties are detectable in living Fischer
rat thyroid follicular cell line 5 (FRTL5) and their nuclei. The investigations indicated further that the new
HYNIC-DAPI derivative is able to interact with double-stranded DNA. This establishes the possibility of
locating 99mTc in close proximity to biological structures of living cells, of which especially the genetic
information-carrying cell compartments are at the centre of interest. In this context, further investigations
are related to the radiotoxic effects of DNA-bound 99mTc-HYNIC-DAPI derivatives and dosimetric
calculations.1. Introduction
Today's level of knowledge in medicine affords a number of
therapeutic options against carcinosis. One important area of
expertise is nuclear medicine, in which beta-emitting radionu-
clides, for instance, 131I, 188Re, 90Y, or 177Lu, are used for ther-
apy.1,2 Recently, the radiometal 99mTc has become of interest.
Because of its gamma radiation at 140 kiloelectron volts
(keV), it is commonly used for scintigraphy in nuclear medi-
cine.3 Furthermore, 99mTc emits an average of five Auger and
internal conversion electrons per decay. Auger processes are
able to damage DNA, depending on the proximity of the
radionuclide to the genetic material.2,4,5 This provides a possi-
bility for radionuclide therapy with 99mTc that has already
been demonstrated by several groups and is the subject of
recent dosimetric investigations.6–9 Various cell experiments
showed that low-energy electrons located outside the cell
nucleus are relatively non-radiotoxic, whereas intranuclear
decay near to DNA causes single- and double-strand
breaks.10–13 The difficulty in the use of Auger emitters inradionuclide therapy is that the radiotracer has to cross
several physiological barriers and also has to be specific
for the nucleus or DNA.14 For this reason, the low accumula-
tion rates of these radiotracers in living cells are the major
limitation for therapeutic use. To take advantage of the
potential of 99mTc as an Auger emitter, the development of
multifunctional radionuclide complexes, which accumulate
in the cell nucleus, is necessary. They include a complex-
ing agent for the radionuclide as a carrier for the transport
through different cell barriers into the nuclei of living cells
and a DNA-binding moiety. There are various studies in
this field of science, for example, with oligonucleotides,15,16
antibodies,17 peptides,18 molecules containing nuclei
localisation sequences (NLS),19 anthracenyl fragments,20,21
desoxyuridine,22 acridine derivatives,18 and Hoechst deriva-
tives23,24 as carriers for different Auger emitters. Based on
these results, we developed a new approach with DAPI, a
commonly used fluorescent dye for staining cell nuclei, as
a carrier for 99mTc. It was first synthesised by Dann et al.
in the search for a new trypanocide and is an analogue of
diarylamidine (berenyl).25 Although not enforced in medical
application until now, DAPI is widely used for biological
and cytochemical investigations.26–28 Among its various bio-
logical effects including antibiotic, antitrypanosomal, and
antiviral activity, it is characterised by the binding to DNA
or ribonucleic acid (RNA).29–31 It was found that two distinctmun., 2015, 6, 887–897 | 887
Scheme 1 Syntheses of compounds 1 and 2. (a) 1. Koshland's reagent,
water, acetone, room temperature, 1 day: 2. formic acid, 10% Pd/C,
TFA, water, 100 °C, 1 day; (b) GABA, Hünig's base, DMF, room
temperature, 1 day.
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View Article Onlinemodes of interaction may occur, depending on the sequence
of DNA: a selective coupling to the minor groove with an
adenine–thymine base pair (AT)-selective, distinct increase
of fluorescence quantum yield and an intercalative binding
to guanine–cytosine base pair (GC) with low fluorescence
that is comparable to the free dye.28,32,33
Our working group aims to develop a combination of the
DNA binder DAPI with the radionuclide 99mTc to investigate
the biological effectiveness of the Auger emitter localised in
the nuclei of living cells. Mainly, DAPI should act as a 99mTc
carrier through different cell barriers and as a DNA-binding
moiety, and the fluorescence of the dye should enable optical
visualisation of the multifunctional compound. Neither DAPI
nor the new derivative was selective for a cell line or a special
tumour tissue. The new radiotracer should act as a tool
for the investigation of the damaging potential of an Auger
emitter under in vitro conditions and should enable the
acquisition of significant data for dosimetric calculations.
To obtain a combination of the fluorescent dye with the
radionuclide, HYNIC was chosen as a chelator for 99mTc,
which was coupled to DAPI through an amide linkage. The
TechnetiumĲV)-HYNIC system was first introduced by
Schwartz et al.34 and allows 99mTc labelling with very high
specific activity under mild conditions. Furthermore, the con-
vertibility of coligands provided the opportunity to influence
the stability or the biodistribution of the 99mTc complex.35,36
Because HYNIC occupies either one or two coordination sites
of 99mTc, the coordination sphere must be completed by a
coligand. The current investigations were made with tricine,
one of the most commonly used coligands, whose com-
plexing reaction with 99mTc is described as fast and efficient
under mild conditions.37–43 To prove the influence of the
spacer between DAPI and HYNIC, different HYNIC-DAPI deri-
vatives were synthesised, which will be presented in forth-
coming publications. This work describes the synthesis and
characterisation of a derivative with a spacer based on
bovine serum albumin (BSA) derivatisation by Li et al.,44
its labelling with 99mTc and gives an introduction to the
in vitro behaviour of the labelled and unlabelled HYNIC-DAPI
derivatives in an FRTL5 cell line. Furthermore, these results
provide a basis for DNA binding experiments, survival studies
in cell culture, and dosimetric calculations based on the
99mTc distribution within various cell compartments.Scheme 2 The synthesis of the new HYNIC-DAPI conjugate. (c) 2,
CDI, DMF, room temperature, 1 day; (d) TFA, room temperature, 1 day;
(e) 4 M HCl, room temperature, 1 h.2. Results
2.1. Chemistry
The fluorochrome DAPI was derivatised on the 3-position of the
phenylindole residue by treatment with 2-hydroxy-5-nitrobenzyl
bromide (Koshland's reagent). Afterwards, the palladium-
catalysed reduction of the nitro group gave compound 1
(Scheme 1-I).44 Then, 5-ĲN′-tert-butoxycarbonylhydrazino)-
pyridine-2-carboxylic acid 2,5-dioxo-pyrrolidin-1-yl-ester
Ĳsuccinimidyl-N-Boc-HYNIC) was reacted with 4-aminobutyric
acid (GABA) in the presence of the base N,N-diisopropylethylamine888 | Med. Chem. Commun., 2015, 6, 887–897(Hünig's base) to introduce the linker for coupling with 1
(Scheme 1-II).
Coupling between 1 and 2 was achieved by activation of
the carboxylate group of 2 using 1,1′-carbonyldiimidazole (CDI)
to give 3 in 14% yield after reversed phase high performance
liquid chromatography (RP-HPLC) purification (Scheme 2-III).This journal is © The Royal Society of Chemistry 2015
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View Article OnlineAfter deprotection and reprotection of 3 by treatment with
trifluoroacetic acid (TFA) for 1 day, the trifluoroacetyl-protected
HYNIC-DAPI (4b) was formed as a 9 : 1 inseparable mixture
with deprotected HYNIC-DAPI (4a). This mixture can be used
for 99mTc labelling without further purification. The
deprotection with 4 M hydrochloric acid (HCl) gives the hydro-
chloride salt of HYNIC-DAPI (4c). The purification of 4c was
tedious, associated with a loss of yield, and inseparable side
products were formed.Fig. 2 RP-HPLC chromatograms of the labelled HYNIC-DAPI deriva-
tives 4c (A) and 4b (B). Signal 1: HYNIC-DAPI derivatives 4c and 4a, sig-
nal 2: trifluoroacetyl-protected HYNIC-DAPI derivative (4b). Detection
was realized by UV ( , 220 nm) and a gamma counter ( ). Monitoring
was achieved by a gradient method with the eluents water and ACN,
both with 0.1% TFA: 100–70% water in 30 min, flow rate 1.4 ml min−1.2.2. Radiochemistry
Both 4a/4b and 4c can be labelled using 99mTc-pertechnetate
in the presence of tinĲII) chloride dihydrate and tricine as
coligand in saline to give 99mTcĲtricine)nHYNIC-DAPI
(Fig. 2). The reaction is complete after an incubation time of
10–15 min at room temperature and led to a specific activ-
ity of up to 0.30 GBq nmol−1. The analysis by RP-HPLC
showed that the labelling of both derivatives resulted in the
same product, whose formal structure is shown in Fig. 1 (5),
hereafter named 99mTc-HYNIC-DAPI.
The RP-HPLC chromatograms of labelled 4c and 4a/4b
Ĳ1/9) are shown in Fig. 2A and B, respectively. The assign-
ment of the most important signals from the UV traces is
given as follows: signal 1—HYNIC-DAPI derivatives 4c and 4a
and signal 2—trifluoroacetyl-protected HYNIC-DAPI deriva-
tive (4b). All further UV signals are caused by side products.
The signal of 99mTc-HYNIC-DAPI was broadened, which was
not unexpected. The comprehensive analysis led to the con-
clusion that within a retention time of 1 min up to three
radioactive signals overlapped. They belong to different spe-
cies of 99mTc-HYNIC-DAPI. However, they could not be sepa-
rated by solid phase extraction (SPE), thin layer chromatogra-
phy (TLC), or RP-HPLC.
Radioactive impurities were detected by instant thin layer
chromatography (ITLC-SG), which showed 16.5 ± 11.0% of
unreduced 99mTc-pertechnetate together with an inseparable
unknown 99mTc degradation product, some reduced hydro-
lysed 99mTc (colloid) below 6%, and 10.1 ± 7.6% of 99mTc-
tricine coligand complex after 15 min reaction time. 99mTc-
HYNIC-DAPI (5) was purified by RP-HPLC and used for
in vitro experiments with the FRTL5 cell culture.This journal is © The Royal Society of Chemistry 2015
Fig. 1 Proposed structure of 99mTcĲtricine)nHYNIC-DAPI with HYNIC
as a monodentate ligand.2.3. In vitro studies
2.3.1. The properties of unlabelled HYNIC-DAPI in cell cul-
ture. The investigation of the spectral characteristics of
HYNIC-DAPI in comparison to DAPI showed that absorption
and fluorescence characteristics did not change significantly
and that the new derivative could be detected using the com-
mon microscope filter for DAPI. The absorption maximum as
well as the fluorescence maximum of HYNIC-DAPI are
slightly red shifted. Hence, excitation for live cell microscopy
had to be higher than that for DAPI, but the basic character-
istics remained.
The addition of 20 μg of DAPI (5.7 × 10−8 mol) or HYNIC-
DAPI (4a/4b = 1/9, 2.8 × 10−8 mol) to FRTL5 cells resulted in
the distribution pattern shown in Fig. 3. The fluorescence
micrographs in Fig. 3A and C show the distribution within
fixed cells, whereas Fig. 3B and D show the live cell images of
DAPI (Fig. 3A and B) and HYNIC-DAPI (Fig. 3C and D).
Fig. 3A and B show the typical fluorescence characteristics of
DAPI with high fluorescence in the cell nuclei and no fluores-
cence enhancement in the cytoplasm. Both images led to the
conclusion that the fluorescence enhancement is restricted to
the nuclei and was inhomogeneous, with different fluores-
cence enhancement from cell to cell. The live cell experi-
ments also showed that the fluorescence increased steadily
for up to 2 h (Fig. 4A). At this time, all nuclei are dyed
(Fig. 3B) and there is no significant difference to the results
of Fig. 3A with fixed cells. The distribution pattern of
HYNIC-DAPI in Fig. 3C and D shows comparable characteris-
tics as described for DAPI. Again, the elevation of the fluores-
cence signal in the nuclei is much higher than that in
the cytoplasm. It seemed to be steady (Fig. 4B) and theMed. Chem. Commun., 2015, 6, 887–897 | 889
Fig. 3 Distribution characteristics of DAPI (A, B) in comparison with
unlabelled HYNIC-DAPI (C, D) in FRTL5 cells. The fluorescence images
(A and C) were recorded using the DAPI filter of an Axioskop 40 micro-
scope (Zeiss) and show the cell nuclei of fixed cells. The live cell
images (B and D) show the correlation of differential interference con-
trast (DIC) technique and DAPI filter (Axio Observer Z.1 microscope
from Zeiss).
Fig. 4 The time-based changes of the fluorescence within the nuclei
of DAPI (A) and HYNIC-DAPI (B) in living FRTL5 cells. The measure-
ments with HYNIC-DAPI were determined with a higher excitation
energy than for DAPI.
Fig. 5 (A) Internalisation characteristics of 99mTc-HYNIC-DAPI.
Method 1 ( ): cells detached with sodium hydroxide; method 2 ( ):
cells treated with nuclei isolation kit. (B) Relative distribution pattern of
99mTc-HYNIC-DAPI from compartmental analysis (method 2) based on
the cell uptake.
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View Article Onlinefluorescence enhancement within the nuclei is also inhomo-
geneous as described for DAPI before. After 2 h, not all cell
nuclei in the live cell experiment are dyed (Fig. 4D), whereas
the enrichment within the nuclei of fixed cells (Fig. 4C) is
more homogeneous and dyes all cell nuclei. All experiments
with fixed cells showed a faster and much higher fluores-
cence enhancement within the nuclei than the live cell exper-
iments, which is high enough to account for exclusive890 | Med. Chem. Commun., 2015, 6, 887–897enrichment in the nuclei as it was expected after fenestration
of the cell membrane. The argument was solely qualitative
because we neither quantified the elevation in quantum yield
nor distinguished if this elevation was caused by enhanced
accumulation within the nuclei or by increasing interaction
with DNA. The time-fluorescence graphs in Fig. 4 gave more
information about the changes in fluorescence in living
FRTL5 cells over the entire measuring time. Background fluo-
rescence is negligible in comparison to that within the
nuclei. The first changes in fluorescence within the nuclei
were measured after 15 min for DAPI (Fig. 4A) and 25 min
for HYNIC-DAPI (Fig. 4B). Then, a steady fluorescence eleva-
tion for both dyes over the entire measuring time occurs and
the qualitative fluorescence increase of DAPI is higher and
faster compared with that of HYNIC-DAPI. The results gave
no evidence about the uptake kinetics of both dyes and the
changes in fluorescence quantum yield between DAPI and
HYNIC-DAPI within the cell nuclei are not comparable.
The fluorescence elevation proved the enrichment of both
dyes within the nuclei of living FRTL5 cells and is an evi-
dence for the local interaction with biological structures, e.g.
the DNA.
2.3.2. The properties of 99mTc-HYNIC-DAPI in cell culture.
To perform the in vitro experiments, an activity of 0.2 MBq of
purified 99mTc-HYNIC-DAPI was given to each well. The
uptakes within the cells for method 1 and method 2 are given
in %. The cell uptake for method 2 was calculated as the
sum of the fractions from the nuclei isolation kit. The
uptakes were calculated based on the added activity of 0.2
MBq and normalised to 5 × 105 FRTL5 cells. The relative
compartment uptake for method 2 was calculated based on
the entire cell uptake and normalised to 1. All results are
decay corrected and, because of the unspecific adsorption of
99mTc-HYNIC-DAPI, also background corrected. The in vitro
behaviour was investigated by two different methods. After
the respective incubation times (see section 5.3), cells were
washed twice with cold phosphate-buffered saline (PBS) and
either detached with sodium hydroxide (method 1) or
separated and fractionated with buffer from the Nuclei EZ
Prep nuclei isolation kit (nuclei isolation kit) (method 2).This journal is © The Royal Society of Chemistry 2015
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View Article OnlineUsing method 1, the results showed a fast accumulation of
1.85 ± 1.09% within one hour after addition of 99mTc-HYNIC-
DAPI ( , Fig. 5A). Up to 24 h, the uptake slows down and
reaches a maximum of 2.81 ± 0.61%. The results of the
preparation with the nuclei isolation kit (method 2) confirmed
these observations. The experiments showed rapid accumulation
within 30 min (1.89 ± 0.33%) and uptakes of 3.10 ± 0.36%
after an incubation time of 24 h ( , Fig. 5A). Fig. 5B
shows the relative ratio of lysate- and nuclei-bound activity,
normalised to the cell uptakes shown in Fig. 5A ( , method 2).
Compared to the increasing cell uptakes, the relative amount
of nuclei-bound activity remains constant. Thus, the cell frag-
mentation indicates that during the entire measurement
period of 24 h about 1/15 of the cell-internalised activity is
located within the nuclei. Based on these results, the
changes in cell uptake were mainly caused by the cytoplasm-
bound activity.
2.4. Stability experiments
Stability experiments were performed with 99mTc-HYNIC-DAPI
in labelling solution at room temperature at pH 5 and in
Gibco F12 culture media at 37 °C at pH 7 over an incubation
time of 24 h (Fig. 6).
The decomposition half-lives of 99mTc-HYNIC-DAPI deriva-
tives in the labelling solution are comparable with that in the
culture medium, on average 8 h. After 24 h, an amount of
16.00 ± 7.08% or 20.56 ± 7.01% of the original compound
remains in the labelling solution or in the culture medium.
Radioactive decomposition products were detected by TLC.
They were identified as reduced hydrolysed 99mTc (colloid),
free 99mTc-tricine coligand complex, and an unknown 99mTc
species. However, they could not be separated by SPE, TLC or
RP-HPLC.
3. Discussion
3.1. Chemistry
After derivatisation of DAPI with Koshland's reagent and
reduction of the nitro-group, the introduction of the HYNIC
chelator to compound 1 was feasible by coupling with 2,
which was synthesised from succinimidyl-N-Boc-HYNIC andThis journal is © The Royal Society of Chemistry 2015
Fig. 6 Stability of 99mTc-HYNIC-DAPI derivatives in labelling solution
(pH 5, room temperature) and culture medium (pH 7.2, 37 °C) over
incubation times of 24 h.GABA. The final tert-butyloxycarbonyl (Boc) deprotection with
TFA gave the new HYNIC-DAPI conjugate as a 1 : 9 mixture of
HYNIC-DAPI 4a and the trifluoroacetyl-protected HYNIC-DAPI
4b. When hydrochloric acid was used, complete deprotection
of HYNIC-DAPI 4c was achieved. During purification of 4c,
side products were formed that could not be separated from
the product. In accordance with the literature, we found that
HYNIC-DAPI is not stable in aqueous solution due to the
high reactivity of the hydrazine group. HYNIC reacts with
impurities that were extracted from various plastic materials
and the resulting hydrazone derivatives block the labelling
reaction.45 To overcome this problem, we used the more sta-
ble trifluoroacetyl-protected HYNIC-DAPI 4b, instead of the
free hydrazine form 4c or 4a.
3.2. Radiochemistry
As described in section 2.2, the labelling of both HYNIC-DAPI
derivatives 4c and 4b led to the same product: 99mTc-HYNIC-
DAPI (5). There is no need to remove the TFA group, whose
advantages and characteristics were already described by
Surfraz et al. for the 99mTc labelling of other trifluoroacetyl-
protected HYNIC derivatives.46,47 The RP-HPLC analysis
showed several 99mTc species with very similar properties,
which contributed to the radioactive signal of 5 (Fig. 2). The
overlapping signals were expected and were caused by a coor-
dination isomerism of the hydrazine bond of the HYNIC resi-
due and the coligand tricine. Although the literature describes
that HYNIC can act as a monodentate ligand as well as a
bidentate ligand and the number of coligands can vary
between 1 and 3, the exact coordination and configuration of
99mTc-coligand-HYNIC complexes is not known.46,48,49
3.3. In vitro studies
3.3.1. The properties of unlabelled HYNIC-DAPI in cell cul-
ture. The distribution characteristics shown in Fig. 3A and B
led to the conclusion that DAPI was enriched in the cell
nuclei of living FRTL5 cells, as described in the literature for
other cell lines. It is also known that the fluorescence quan-
tum yield of DAPI in aqueous solution is negligible26,50 and
that the remarkable increase of fluorescence quantum yield
is caused by an AT-selective minor groove binding to
DNA.26,29,31,50 The results in Fig. 3A and B prove that enrich-
ment of DAPI in the nuclei of fixed and living FRTL5 cells
goes along with an interaction with the DNA. Fig. 3C and D
also show that the unlabelled HYNIC-DAPI (4a/4b) is able to
cross the cell membranes of living FRTL5 cells. Furthermore,
a qualitative analysis demonstrated a higher elevation of fluo-
rescence in the nuclei than in the cytoplasm for both dyes
(Fig. 4). In comparison with DAPI, the fluorescence signal of
HYNIC-DAPI in aqueous solution is insignificant. Therefore it
is likely that the enrichment in the nuclei is also related to
an interaction with the DNA of living FRTL5 cells. The mea-
surements gave no information about the kinetics of inter-
nalisation of DAPI and HYNIC-DAPI. The change of the
quantum yield indicated the interaction of both dyes withMed. Chem. Commun., 2015, 6, 887–897 | 891
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View Article Onlinebiological structures, e.g. the DNA, but did not allow to
determine the quantitative uptake into the cell compart-
ments. The changes in fluorescence enhancement of both
dyes, as seen in Fig. 4, were not comparable. As described in
the literature, the fluorescence quantum yield depends on
the composition of the DNA, e.g. the conformation or the AT
content, thereby on the disposability of binding sites, and
the type of interaction.29–33 This is one reason why the fluo-
rescence intensity within the cell nuclei seemed inhomoge-
neous for both dyes. Furthermore, the enrichment within the
cell nuclei is dependent on involved transport mechanisms
during influx and efflux and on cell-specific decomposition
mechanisms. To date, the transport routes and the metabo-
lism of DAPI were mainly unresolved, but it was assumed
that multitude pathways are involved.51,52 The efficiency of
decomposition and transport mechanisms of DAPI and
HYNIC-DAPI may be dependent on the individual state of the
cells, e.g. the vitality, the integrity of cell membranes, extrane-
ous influences, and the phase of the cell cycle. These influ-
ences on the in vitro behaviour may also cause the inhomoge-
neous enrichment. The requirement for the comparison of
DAPI and HYNIC-DAPI in Fig. 4 is the knowledge of the
affinity, the binding mode, and the individual factor for the
enhancement of the fluorescence quantum yield for the
special interaction with the DNA of FRTL5 cells. So far, we
were not able to quantify the elevation in quantum yield in
the nuclei of living FRTL5 cells, but the qualitative studies
suggest an interaction between HYNIC-DAPI and DNA
as described for DAPI before. The investigation of the
HYNIC-DAPI derivatives with calf thymus DNA (ctDNA) will
be investigated in further studies. First results of the effects
of 99mTc-HYNIC-DAPI on plasmid DNA have already been
published.13
3.3.2. The properties of 99mTc-HYNIC-DAPI in cell culture.
Uptake experiments showed that 99mTc-HYNIC-DAPI is able
to cross the cell membranes of living FRTL5 cells and corre-
lated with the qualitative fluorescence data. The inability to
characterise the 99mTc species of HYNIC-DAPI is not unex-
pected46,48,49 but does create problems in understanding
which radiochemical species may be responsible for cell
uptake and internalisation into the nuclei. The comparison
of the uptake results, obtained with two different methods,
showed good correlation within an incubation time of 24 h.
The determined uptake maxima were 2.81 ± 0.61% for
method 1 and 3.10 ± 0.36% for method 2 (Fig. 5A). Further-
more, both methods showed that the accumulation within
1 h is initially fast and then slows down. This seemed to be a
strange uptake pattern and indicated the influence of inter-
fering parameters. From our point of view, the most impor-
tant parameter is the unspecific adsorption of the 99mTc-
HYNIC-DAPI species to the plastic wells which also caused
the large error bars. Hence, reference measurements were
performed and all uptakes were background corrected.
Based on the results of the compartment analysis (nuclei
isolation kit, method 2), the amount within the nuclei is on
average 1/15 of the cell-internalised activity. Although892 | Med. Chem. Commun., 2015, 6, 887–89799mTc-HYNIC-DAPI showed enrichment and distribution
within the whole cells, it cannot be considered to be specific
for an interaction with the DNA of living FRTL5 cells. Further
investigations of our group confirm the thesis of a direct
interaction with free DNA and prove that 99mTc-HYNIC-DAPI
is bound to plasmid DNA, introducing 4-fold more single-
strand breaks (SSB) and up to 10-fold more double-strand
breaks (DSB) than free 99mTc sodium pertechnetate.13
As shown in section 2.4, the decomposition half-life of
99mTc-HYNIC-DAPI is about 8 h in culture medium. Decom-
position influences the internalisation into the cells and the
distribution between the cell compartments, e.g. into the
nuclei. Therefore, the limited disposability of 99mTc-HYNIC-
DAPI could be the explanation for the decreasing uptake
kinetics from 1 to 24 h and the constant amount of activity
within the cell nuclei. It is likely that the plateau in the
uptake curve (Fig. 5A) is caused by the stopped inter-
nalisation of 99mTc-HYNIC-DAPI and the residue of the
decomposition products within the cell compartments. This
means that the decomposition products neither internalise
into cells nor move within the cell compartments. The influ-
ence of 99mTc sodium pertechnetate is negligible because all
uptake experiments were achieved with purified
99mTc-HYNIC-DAPI. The internalisation of reduced hydro-
lysed 99mTc (colloid) in cells is not considerable. The uptakes
of the 99mTc-tricine coligand complex and of the unknown
99mTc decomposition products could be approximately
determined from the other decomposition products. The
measurements with reference preparations suggest that the
uptake of these products is negligible and that there is no
enrichment into the cell nuclei (data not shown). Possible
and, to date, unknown further impairments of the in vitro
behaviour are cell-specific decomposition mechanisms and
influences of involved transport mechanisms, as described in
section 3.3.1.
3.4. Stability
The experiments showed a lower stability of 99mTc-HYNIC-
DAPI (5), as expected. In further investigations, the use of
another coligand may give a higher stability of the complex
that may finally result in a higher uptake. The stability of the
complex with tricine as a coligand in the labelling solution is
comparable with that in the culture medium. After 1 day,
approximately 20% of intact complex was detected. Three
species of decomposition products were identified by ITLC-
SG: reduced hydrolysed 99mTc (colloid), 99mTc-tricine
coligand, and one unknown 99mTc species. The characterisa-
tion of the 99mTc-tricine coligand species and the unknown
decomposition products of 99mTc-HYNIC-DAPI was not possi-
ble because they could not be isolated by SPE or RP-HPLC.
4. Conclusion
A new HYNIC-DAPI derivative for labelling with the radionu-
clide 99mTc was successfully designed. The labelling proce-
dure is a simple batch preparation that leads to high specificThis journal is © The Royal Society of Chemistry 2015
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View Article Onlineactivity. The fluorescence micrographs and several in vitro
experiments proved that the labelled as well as the unlabelled
HYNIC-DAPI derivatives were able to cross different cell bar-
riers and enrich within the nuclei of living FRTL5 cells. The
enrichment may be influenced or limited by various parame-
ters, e.g. stability, the isomerism of the coligand complex, the
unspecific adsorption, together with cell-specific decomposi-
tion and transport mechanisms. No reference data about
uptake mechanisms and the distribution ratio of DAPI in liv-
ing cells are available so far, which creates problems in
understanding the in vitro behaviour of the new HYNIC-DAPI
derivative. To overcome these limitations, further experi-
ments with DAPI and HYNIC-DAPI in other cell lines could
offer a better understanding of the internalisation mecha-
nism. Moreover, the low stability of 99mTc-HYNIC-DAPI limits
the accumulation rate and may be improved by another
coligand which may lead to higher cell or nuclei uptakes.
Furthermore, the unlabelled and the labelled HYNIC-DAPI
are similar in their (bio)chemical properties and in vitro
behaviour. The qualitative analysis of the experiments with
fixed and living cells indicated an enrichment within the cell
nuclei by shifting the quantum yield and confirmed the
results of the uptake measurements. As mentioned before,
we neither quantified the elevation in quantum yield nor
determined the binding mode in the HYNIC-DAPI–DNA
complexes.
The new HYNIC-DAPI derivative gives no ability for any
therapeutic use in Auger emitter radiotherapy. Neither DAPI
nor HYNIC-DAPI is selective for a cell line or a special
tumour tissue. The goals of this work were the development
of a multifunctional compound with DAPI as a carrier for
99mTc, the radiolabelling, and the in vitro evaluation in an
FRTL5 cell line. These results provide a basis for the quantifica-
tion of radiotoxic effects and dosimetric parameters for the dam-
aging potential of an Auger emitter under in vitro conditions.
5. Experimental section
5.1. Chemistry
All reagents and solvents were purchased from Appli Chem,
TCI, Fluka, Merck, and Sigma Aldrich. 6-Boc-hydrazinopyridine-
3-NHS was synthesised as described in the literature.40 All
chemical reagents were of highest commercially available
quality and were used without further purification. Analytical
high performance liquid chromatography (HPLC) analyses
for compounds 1, 2, 3, and 4 were performed using an
Agilent 1100 HPLC (Agilent Technologies, Böblingen, Baden-
Württemberg, Germany) with a quaternary pump, a UV/Vis
detector, and an autosampler. For compounds 1–3 and 4a/4b,
the system was equipped with a Sunfire® C18 column
(4.6 × 250 mm, 5 μm). Monitoring was achieved by a gradient
method with the eluents water and acetonitrile, both
with 0.1% TFA: 100–60% water (0–30 min), 60–30% water
(30–40 min), flow rate 1 ml min−1. UV detection was per-
formed at wavelengths of 220, 280, 308, and 326 nm. The
analytical system for compound 4c was equipped with a YMCThis journal is © The Royal Society of Chemistry 2015ODS-A C18 column (4.6 × 250 mm, 5 μm). Monitoring was
achieved by a gradient method with the eluents water and
acetonitrile, both with 0.1% 12 M HCl: 100–60% water
(0–30 min), flow rate 1 ml min−1. UV detection was set at
220 nm. BocHYNIC-DAPI 3 and deprotected HYNIC-DAPI 4c
were purified by preparative HPLC (Merck-Hitachi LaChrome
D-7000) with an L-7100 pump and an L-7400 UV detector
(Merck, Darmstadt, Hesse, Germany). The system was equipped
with a Sunfire® Prep C18 OBD column (30 × 250 mm, 10 μm).
The eluents for purifying 3 were water and acetonitrile, both
with 0.1% trifluoroacetic acid (TFA): 20% acetonitrile, iso-
cratic conditions, flow rate 20 ml min−1. UV detection was set
at 220 nm. Purification of 4c was achieved with the eluents
water and acetonitrile, both with 0.1% 12 M HCl: 100–60%
water (0–40 min), flow rate 20 ml min−1. UV detection was set
at 220 nm.
1H-NMR and 13C-NMR spectra were recorded using a
Bruker spectrometer (Bruker BioSpin GmbH, Rheinstetten,
Baden-Württemberg, Germany) in deuterated dimethyl sulf-
oxide (DMSO-d6) or deuterated methanol (CD3OD). The
chemical shifts are reported in parts per million (ppm), and
the coupling constants ( J) are reported in hertz (Hz). The cen-
tre lines of the multiplets of dimethyl sulfoxide (DMSO) or
CD3OD were defined as 2.5 and 3.3 ppm, respectively, and
were used as internal references for the 1H-nuclear magnetic
resonance (NMR) spectra. Electrospray ionisation mass spec-
tra (ESI-MS) were obtained using an MSQ mass detector
(Thermo Fisher Scientific, Waltham, Massachusetts, USA).
99mTc labelling was performed with fresh eluate from a
99Molybdenum Ĳ99Mo)/99mTc generator (Ultra-Technekow™
FM, Covidien, Neustadt a. d. Donau, Bayern, Germany). Anal-
ysis and purification of the labelling products were
performed using a Merck Hitachi Elite La Chrome HPLC
instrument consisting of a pump, an L2420 UV-vis detector,
and an L2300 column oven (Merck, Darmstadt, Hesse, Ger-
many). The system was equipped with a Chromolith® Perfor-
mance HPLC column RP18e (100 × 4.6 mm, 5 μm). The moni-
toring and purification of the labelling products were
achieved by two different methods. The eluents were
water and acetonitrile, both with 0.1% trifluoroacetic acid.
The UV detection was set at 220 nm. Monitoring: 0–30% ace-
tonitrile (0–30 min), flow rate 1.4 ml min−1. Purification: 11–
16% acetonitrile (0–20 min), flow rate 1.2 ml min−1.
TLC was performed using an ITLC-SG (Varian) with saline,
2-butanone and a mixture of acetonitrile/water/trifluoroacetic
acid 2/2/0.1 Ĳv/v/v) as solvents. The chromatography paper
was analysed using a VCS 203 scanner from Veenstra (version
2.01). All radioactive samples from the in vitro experiments
were measured with the Isomed 2000 V1.22 (MED
Nuklearmedizintechnik Dresden GmbH, Dresden, Saxony,
Germany) or with the gamma-counter COBRA™ II Auto-
Gamma (Packard).
5.1.1. 3-Ĳ5-Amino-2-hydroxybenzyl)-2-Ĳ4-carbamimidoylphenyl)-
1H-indole-6-carboxamidine TFA salt (1). Step 1: 2.85 mmol of
4,6-diamidin-2-phenylindole dihydrochloride (1.00 g, 1 eq.) was
dissolved in 50 ml of water and 27 ml of acetone. A solution ofMed. Chem. Commun., 2015, 6, 887–897 | 893
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View Article Online1.2 eq. Koshland's reagent (3.45 mmol, 0.80 g) in 27 ml of ace-
tone was added and the mixture was stirred at room tempera-
ture. After 22 h, a second portion of 0.2 eq. Koshland's reagent
(0.69 mmol, 0.16 g) was added and the reaction mixture was
stirred for another 22 h. Then, the solvents were evaporated and
the residue was dissolved in methanol. The mixture was evapo-
rated again, and the resulting yellow precipitate was suspended
in chloroform and stirred overnight. The solid was filtered and
washed twice with chloroform and once with water to give 61%
(1.73 mmol, 0.74 g) of product.
Analytical HPLC: retention time (tR) = 22.2 min. δH
(CD3OD, 500 MHz) [ppm] 8.05 (s, 1 H), 8.00 (dd,
3J = 8.9 Hz,
4J = 2.7 Hz, 1 H), 7.93 (d, 3J = 8.3 Hz, 2 H), 7.85 (d, 3J = 8.3
Hz, 2 H), 7.63 (d, 3J = 8.4, 1 H), 7.56 (d, 4J = 2.5 Hz, 1 H), 7.46
(dd, 3J = 8.4 Hz, 4J = 1.1 Hz, 1 H), 6.97 (d, 3J = 8.9 Hz, 1 H),
4.33 (s, 2 H). δC (CD3OD, 126 MHz) [ppm] 169.43, 162.93,
141.89, 139.80, 139.07, 137.53, 134.71, 129.86, 129.83, 129.59,
129.20, 125.69, 125.08, 123.23, 121.14, 119.79, 115.70, 113.47,
112.51, 25.09.
Step 2: 1.26 mmol (0.63 g, 1 eq.) of the product from step
1 was dissolved in 71 ml of formic acid. Then 2.70 g of 10%
Pd/C and 23.7 ml of a 1 : 1 mixture of trifluoroacetic acid and
water were added successively. The reaction mixture was
heated to 100 °C for 18 h. It was filtered through celite, the
residue was washed with formic acid, and the filtrate was
evaporated to yield 99% (1.24 mmol, 0.92 g) of a yellow solid.
Analytical HPLC: tR = 16.3 min. δH (CD3OD, 500 MHz)
[ppm] 8.06–8.11 (m, 3 H), 8.03 (d, 4J = 1.3 Hz, 1 H), 7.92 (d, 3J
= 8.6 Hz, 2 H), 7.85 (d, 3J = 8.6 Hz, 2 H), 7.62 (d, 3J = 8.4 Hz,
1 H), 7.45 (dd, 3J = 8.5 Hz, 4J = 1.7 Hz, 1 H), 7.04 (dd, 3J = 8.6
Hz, 4J = 2.8 Hz, 1 H), 6.95 (d, 3J = 8.6 Hz, 1 H), 6.75 (d, 3J =
2.7 Hz, 1 H), 4.31 (s, 2 H). δC (CD3OD, 126 MHz) [ppm]
169.12, 162.58, 157.09, 139.76, 138.98, 137.60, 134.92, 130.54,
129.80, 129.79, 129.70, 129.12, 124.43, 123.33, 122.96, 122.88,
121.26, 119.64, 116.75, 113.34, 113.06, 25.16.
5.1.2. 4-{[6-ĲN′-tert-Butoxycarbonyl-hydrazino)-pyridine-3-
carbonyl]-amino}-butyric acid (2). A 2.85 mmol (0.29 g, 1 eq.)
sample of GABA was dissolved in 12 ml of N,N-dimethyl-
formamide (DMF), and then 4 eq. (11.47 mmol, 1.95 ml)
Hünig's base and 1 eq. (2.85 mmol, 1.00 g) succinimidyl-N-
Boc-HYNIC were added. The reaction mixture was stirred for
23 h at room temperature. DMF was evaporated and the
product was dried overnight to obtain a yellow oil. The crude
product was purified by column chromatography with methy-
lene chloride/ethyl acetate/methanol 5/5/1 Ĳv/v/v) to afford 2
as a white solid in 50% yield (1.43 mmol, 0.48 g).
Analytical HPLC: tR = 18.6 min. δH (DMSO-d6, 500 MHz)
[ppm] 12.03 (br s, 1 H), 8,92 (br s, 1 H), 8.65 (s, 1 H), 8.53 (d,
4J = 1.6 Hz, 1 H), 8.29 (t, 3J = 5.4 Hz, 1 H), 7.94 (d, 3J = 8.7 Hz,
1 H), 6.50 (d, 3J = 8.8 Hz, 1 H), 3.24 (dd, 2J = 12.7 Hz, 3J = 6.7
Hz, 2 H), 2.26 (t, 3J = 7.3 Hz, 2 H), 1.68–1.76 (m, 2 H), 1.42 (s, 9
H). δC (DMSO-d6, 126 MHz) [ppm] 165.04, 161.61, 155.86,
147.79, 136.64, 120.59, 104.63, 79.24, 38.50, 31.30, 28.16, 24.70.
5.1.3. N′-ĳ5-Ĳ3-{3-ĳ6-Carbamimidoyl-phenyl)1H-indol-3-ylmethyl]-
4-hydroxyphenylcarbamoyl}-pyridin-2-yl]-hydrazinecarboxylic
acid tert-butyl ester TFA salt (3). A 1.23 mmol (0.91 g, 1 eq.)894 | Med. Chem. Commun., 2015, 6, 887–897sample of compound 2 was dissolved in 12.6 ml of DMF. Then 1
eq. of CDI (2.29 mmol, 0.37 g) was added and the mixture was
stirred for 1 h under exclusion of light. Afterwards, 1.85 eq. of 1
(2.29 mmol, 0.77 g) in 7 ml of DMF was added dropwise to the
solution of 2 and the reaction mixture was stirred for 24 h under
exclusion of light at room temperature. The solvent was removed,
and the residue was purified by preparative HPLC and dried over-
night to yield 14% (0.18 mmol, 0.19 g) of a yellow solid.
Analytical HPLC: tR = 26.2 min. δH (DMSO-d6, 500 MHz)
[ppm] 12.23 (s, 1 H), 9.45 (s, 2 H), 9.34 (s, 2 H), 9.23 (s, 2 H),
9.22 (s, 3 H), 9.04 (br. s, 1 H), 8.99 (s, 3 H), 8.47 (d, 4J = 1.8
Hz, 1 H), 8.30 (s, 1 H), 7.97–7.89 (m, 2 H), 7.95 (d, 3J = 8.3
Hz, 2 H), 7.83 (d, 3J = 8.5 Hz, 2 H), 7.57 (d, 3J = 8.4 Hz, 1 H),
7.41 (dd, 3J = 8.5 Hz, 4J = 1.3 Hz, 1 H), 7.36 (dd, 3J = 8.6 Hz,
4J = 2.4 Hz, 1 H), 6.82 (d, 4J = 2.3 Hz, 1 H), 6.80 (d, 3J = 8.7 Hz,
1 H), 6.59 (d, 3J = 8.0 Hz, 1 H), 4.15 (s, 2 H, H-9), 3.16 (dd,
3J = 6.2 Hz, 2J = 13.2 Hz, 2 H), 2.13 (t, 3J = 7.4 Hz, 2 H), 1.62–
1.71 (m, 2 H), 1.42 (br s, 9 H).
δC (DMSO-d6, 126 MHz) [ppm] 169.95, 166.36, 165.00,
164.54, 155.70, 150.73, 146.44, 137.48, 136.69, 135.44, 135.04,
132.81, 131.18, 128.72, 127.75, 127.28, 126.47, 121.37, 120.57,
119.77, 119.53, 119.00, 118.59, 118.56, 118.45, 114.52, 112.18,
112.03, 79.42, 38.65, 33.56, 28.06, 25.22, 24.12.
m/z [M + H]+ 719.3, calculated 719.3; [M + TFA-H]− 831.5,
calculated 831.3.
5.1.4. N-Ĳ4-Ĳ3-Ĳ(6-Carbamimidoyl-2-Ĳ4-carbamimidoylphenyl)-
1H-indol-3-yl)methyl)-4-hydroxyphenylamino)-4-oxobutyl)-
6-Ĳ2-Ĳ2,2,2-trifluoracetyl)hydrazinyl)nicotinamide TFA salt (4b).
A 0.05 mmol (0.05 g) sample of bocHYNIC-DAPI (3) was
dissolved in trifluoroacetic acid. The reaction mixture was
stirred for 22 h under the exclusion of light at room tempera-
ture. The solvent was evaporated, and the residue was
dissolved in diethyl ether and stirred for 2 h at room tempera-
ture. Afterwards, the solvent was removed and the residue was
washed twice with diethyl ether. The product was evaporated
and dried. 36 mg (0.05 mol) of compound 4 were obtained as
a 1 : 9 mixture of HYNIC-DAPI (4a) and trifluoroacetyl-
protected HYNIC-DAPI (4b).
Analytical HPLC: tR (4b) = 20.7 min. δH (DMSO-d6, 500
MHz) [ppm] 4b 12.22 (s, 1 H), 9.47–9.41 (m, 2 H), 9.34 (s, 2
H), 9.23 (s, 2 H), 9.19 (s, 2 H), 8.96 (s, 2 H), 8.51 (s, 1 H), 8.31
(t, 3J = 5.35 Hz, 1 H), 7.97–7.90 (m, 4 H), 7.83 (d, 3J = 8.37
Hz), 7.57 (d, 3J = 8.70 Hz, 1 H), 7.41 (dd, 3J = 8.40, 4J = 1.30
Hz, 1 H), 7.36 (dd, 3J = 8.53 Hz, 4J = 2.17 Hz, 1 H), 6.82 (d,
4J = 2.34 Hz, 1 H), 6.80 (d, 3J = 8.70 Hz, 1 H), 6.66 (d, 3J = 8.70
Hz, 1 H), 4.15 (s, 2 H), 3.16 (q, 3J = 6.58 Hz, 2 H), 2.13 (t, 3J =
7.36 Hz, 2 H), 1.67 (quin, 3J = 7.36 Hz, 2 H). δC (DMSO-d6,
125 MHz) [ppm] (4b) 176.22, 170.00, 166.34, 165.00, 164.57,
150.79, 137.54, 136.71, 135.48, 132.86, 131.24, 128.82, 127.78,
127.36, 126.52, 123.18, 121.44, 119.75, 119.61, 118.64, 118.46,
117.75, 115.42, 114.55, 112.25, 112.04, 38.70, 33.56, 25.23,
24.16.
m/z (4a) [M + H]+ 619.4, calculated 619.3; [M + TFA-H]−
731.3, calculated 731.3. (4b) [M + H]+ 715.4, calculated 715.3;
[M + TFA-H]− 827.4, calculated 827.3; [M − H]− 713.6, calcu-
lated 713.3.This journal is © The Royal Society of Chemistry 2015
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View Article Online5.1.5. N-Ĳ4-Ĳ3-Ĳ(6-Carbamimidoyl-2-Ĳ4-carbamimidoylphenyl)-
1H-indol-3-yl)methyl)-4-hydroxyphenylamino)-4-oxobutyl)-
6-Ĳ2-hydrazinyl)nicotinamide hydrochloride (4c). A 0.04 mmol
(0.04 g) sample of Boc-HYNIC-DAPI (3) was dissolved in 4 M
HCl. The reaction mixture was stirred for 1 h under the exclu-
sion of light at room temperature. The product was purified by
preparative RP-HPLC, evaporated, and dried to yield 62.7%
(0.02 mmol, 0.015 g) of a yellow solid.
Analytical HPLC: tR = 18.8 min. δH (DMSO-d6, 500 MHz)
[ppm] 12.49–12.32 (m, 1 H), 9.67 (br. s., 1 H), 9.58–8.62 (m,
13 H), 8.24 (br s., 1 H), 8.06–7.74 (m, 6 H), 7.55 (d, 3J = 7.70
Hz, 1 H), 7.39 (m, 2 H), 6.97–6.47 (m, 3 H), 4.13 (br. s., 2 H),
3.63–3.05 (m, 2 H), 2.21–2.00 (m, 2 H), 1.57–1.80 (m, 2 H). δC
(DMSO-d6, 125 MHz) [ppm] 169.36, 165.71, 164.32, 150.11,
148.31, 136.81, 136.04, 134.80, 132.15, 130.50, 128.12, 127.10,
126.41, 125.81, 123.48, 120.56, 119.11, 119.00, 118.84, 117.87,
117.76, 113.86, 111.68, 111.26, 32.88, 25.49, 23.48.
m/z [M + H]+ 619.4, calculated 619.3; [M + K]+ 657.2, cal-
culated 657.3.
5.2. Radiochemistry
Labelling was achieved with 7.0 × 10−9 mol of HYNIC-DAPI
and 2 GBq of fresh 99mTc sodium pertechnetate from a 99Mo/
99mTc generator system in 1.0–1.5 ml of saline (Fresenius
Kabi), and 200 μl of a stock solution of 1.12 × 10−1 mol of
tricine, containing 5.32 × 10−4 mol of tinĲII) chloride
dihydrate ĲSnCl2Ĵ2H2O), was added. The reaction mixture was
incubated for 15 min at room temperature. After quality con-
trol by TLC, the labelling product was purified by RP-HPLC
and used for stability analysis or in vitro experiments with
the FRTL5 cell culture.
5.3. Cell culture experiments
All chemicals and culture media were purchased from
Invitrogen, Biochrom AG, Merck, and Sigma-Aldrich. The
FRTL5 cell line was obtained from the National Centre for
Radiation Research in Oncology (OncoRay, Dresden). The
nuclei isolation kit was purchased from Sigma Aldrich. For
the uptake experiments, cells were grown in 6-well multititer
plates (MTPs) (Becton Dickinson). Cells for live cell micros-
copy were sowed in special petri dishes from Ibidi and those
for the experiments with fixed cells in LabTekII chamber
slides from Nunc. All cells were grown for 1 day in a CB150
or CB150E incubator from Binder in an atmosphere
containing 5% carbon dioxide at 37 °C. After the addition of
purified 99mTc-HYNIC-DAPI, the cells were incubated in an
IG150 incubator from Jouan with 5% carbon dioxide at 37
°C. Cell counting, growth control, and the analysis of fixed
cells were performed using an Axioskop 40 microscope from
Zeiss. For live cell microscopy, an Axio Observer Z.1 micro-
scope by Zeiss with an incubator from Pecon was used. Both
microscopes were equipped with a filter for transmitted light
and a DAPI filter (λEx 360 nm, λEm 460 nm).
5.3.1. Tissue preparation. FRTL5 cells were grown in
Gibco® F12 + Gluta2MAX™-I culture medium (Invitrogen)This journal is © The Royal Society of Chemistry 2015with the following additives: 5% foetal calf serum (FCS),
10 nmol l−1 hydrocortisone, 5 μg ml−1 transferrin, 10 ng ml−1
somatostatine, 10 ng ml−1 of the amino acids glycine, histi-
dine, and lysine, 10 mU ml−1 thyroid stimulating hormone
(TSH), and 10 μg μl−1 insulin. For the uptake (6-well MTPs)
and live cell experiments (petri dishes), 2.5 × 105 cells per
cavity were grown. For the experiments with fixed cells, 3 ×
105 cells were grown in chamber slides. Before starting an
experiment, the culture medium was replaced with 2 ml of
fresh medium, including the required amount of labelled or
unlabelled HYNIC-DAPI. Reference experiments were performed
with 2 ml of renewed culture medium without any additions.5.3.2. Fluorescence microscope analysis
For the fixation experiments, 3 × 105 FRTL5 cells were grown
for 1 day in 2 ml of culture medium. Then the supernatant
was removed and the cells were washed twice with 1 ml of
cold PBS (4 °C). They were fixed with 0.5 ml of 1% formalde-
hyde (Sigma Aldrich) in PBS buffer for 15 min and washed
three times with 1 ml of PBS for 5 min at room temperature.
For the permeabilisation, all cells were incubated three times
with 0.5 ml of 0.1% Triton X-100 (Merck) in PBS buffer for 5
min at room temperature and then washed three times with
1 ml of PBS for 5 min at room temperature. The pretreated
cells were incubated with 1.4 × 10−8 mol of DAPI (5 μg) or
HYNIC-DAPI (10 μg) for 1 h in 2 ml of fresh culture medium
at 37 °C. The cells were washed twice with 1 ml of PBS at
room temperature and the chamber was removed. The cells
were surfaced with fluorescence mounting medium, covered
with a cover glass and were analysed using the DAPI filter of
the fluorescence microscope (Axioskop 40, Zeiss).
For live cell imaging, 2.5 × 105 cells per cavity were incu-
bated with 20 μg of DAPI (5.71 × 10−8 mol) or HYNIC-DAPI
(2.8 × 10−8 mol), respectively, in 1.5 ml of fresh, temperature-
controlled (37 °C) culture medium. After each 5 min interval,
images with exposure times of 20 ms (DAPI) and 350 ms
(HYNIC-DAPI) were recorded using a DAPI filter. The visuali-
sation with the DIC technique was conducted simultaneously
with exposure times of 50 ms. All images were recorded using
the 40×-oil object lens of an Axio Observer Z.1 microscope
(Zeiss). The overall measuring time lasted 2 h. Changes in
fluorescence intensities were determined using the free soft-
ware Fiji 1.46 and its region of interest (ROI) manager tool.
Into the cell nuclei and the background of all images, respec-
tively, 1000 or 30 ROIs were located. The mean values of every
image gave the fluorescence emission curve as seen in Fig. 4.
5.3.3. Uptake experiments. 2.5 × 105 cells were grown in
three of six cavities of the 6-well MTPs. The remaining three
cavities without cells served as references to estimate back-
ground binding. All cavities were treated similarly. Each well
was incubated with 0.2 MBq of purified 99mTc-HYNIC-DAPI
in 2 ml of fresh, temperature-controlled (37 °C) culture
medium and placed in the incubator. The uptake was
observed over 24 h (5, 10, 15, and 30 min and 1, 2, 4, 8, and
24 h). At chosen incubation times, the respective MTPs wereMed. Chem. Commun., 2015, 6, 887–897 | 895
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View Article Onlineplaced on ice for 2 min and the supernatant was removed.
All cavities were washed twice with 1 ml of cold (4 °C) PBS.
Cells were detached with 1 ml of 0.1 N sodium hydroxide. All
fractions were collected separately and measured with the
gamma-counter.
The cell uptake was calculated based on the added activity
of 0.2 MBq and is given in %. It is decay and background
corrected and normalised to 5 × 105 FRTL5 cells.
5.3.4. Uptake experiments with cell fractionation. Six-well
MTPs were handled similarly as in standard uptake experi-
ments (see section 3). Investigations were also conducted
after 5, 10, 15, and 30 min and 1, 2, 4, 8, and 24 h. The
respective multiwell plates were placed on ice for 2 min and
the supernatant was removed. Cell nuclei were separated
according to the protocol for the commercially available
nuclei isolation kit. All fractions were collected separately
and measured with the gamma-counter. The cell uptake was
calculated from the sum of the compartment fractions based
on the added activity of 0.2 MBq, is background corrected,
normalised to 5 × 105 FRTL5 cells, and is given in %. The rel-
ative compartment uptake was calculated based on the cell
uptake and normalised to 1.
5.4. Stability experiments
The stability of 99mTc-HYNIC-DAPI was investigated by TLC
in the labelling solution and in culture medium after incuba-
tion times of 5, 10, 15, and 30 min and 1, 2, 4, 8, 24, and 48
h. The experiments were performed under the following
conditions:
1. in labelling solution: pH 5, room temperature, with no
further add-on;
2. in culture medium: pH 7, 37 °C, dilution of 50 μl (ca.
100 MBq) of purified 99mTc-HYNIC-DAPI in 0.5 ml of fresh,
temperature-controlled culture medium.
Both mixtures were incubated and shaken at 350 rpm at
temperature control.
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